Core Viewpoint - He Yuan Bio (688765) anticipates a net profit loss of between 143 million yuan and 167 million yuan for the year 2025, despite rapid revenue growth from its product Aofumin (recombinant human albumin injection) entering the market [1] Group 1: Financial Performance - The company projects a net profit loss of -143 million to -167 million yuan for 2025 [1] - The overall performance remains in a loss state due to various factors, including ongoing high R&D investments [1] Group 2: Product Development and Market Entry - Aofumin has been approved for market entry, contributing to rapid revenue growth [1] - The production line for the recombinant human albumin is still in the capacity ramp-up phase, with gradual capacity release expected [1]

Core Viewpoint - He Yuan Bio (688765.SH) expects a net profit attributable to shareholders of the parent company to be between -167 million and -143 million yuan for the year 2025 [1] Group 1: Financial Performance - The main reason for the performance change is the rapid growth in sales revenue following the approval and market introduction of the product Aofumin (recombinant human albumin injection) [1] - The production line for the annual output of 10 tons of recombinant human albumin raw liquid and preparations is still in the capacity ramp-up phase, with capacity expected to be gradually released [1] - Despite these factors, the company remains in a state of overall performance loss due to continued high levels of R&D investment [1]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Core Viewpoint - He Yuan Bio (688765.SH) is expected to report significant losses in 2025, with total profit estimated between -167 million to -143 million yuan, and net profit attributable to shareholders also projected in the same range [1] Financial Performance - The company anticipates a revenue of 45 million to 50 million yuan for 2025, representing a year-on-year increase of 78.46% to 98.29% [1] - After excluding non-recurring gains and losses, the net profit attributable to shareholders is expected to be between -191 million to -162 million yuan [1] Key Factors Influencing Performance - The rapid growth in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) [1] - The production line for the related product, with an annual capacity of 10 tons of recombinant human albumin, is still in the ramp-up phase, with capacity expected to gradually increase [1] - The company continues to maintain high levels of investment in research and development, contributing to the overall loss during the reporting period [1]

Core Viewpoint - He Yuan Bio is expected to report a net loss of between 143 million to 167 million yuan for the year 2025, indicating ongoing financial challenges despite product launches and revenue growth [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -191 million to -162 million yuan for 2025 [1] - The overall performance remains in a loss state during the reporting period due to various factors [1] Product Development - The product "Aofumin" (recombinant human albumin injection) has been approved for market entry, contributing to rapid revenue growth [1] - The production line for the annual output of 10 tons of recombinant human albumin is still in the capacity ramp-up phase, with gradual capacity release expected [1] Research and Development - The company continues to maintain high levels of investment in research and development [1]

Financial Projections - The company expects a total profit loss of between -167 million and -143 million yuan for the year 2025, with a net profit attributable to shareholders of the parent company also in the range of -167 million to -143 million yuan[3]. - The projected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -191 million and -162 million yuan[3]. - The anticipated operating revenue for 2025 is between 45 million and 50 million yuan, representing a year-on-year increase of 78.46% to 98.29%[3]. - The operating revenue, after excluding unrelated business income and income without commercial substance, is also expected to be between 45 million and 50 million yuan[3]. - In the same period last year, the total profit was -151.37 million yuan, and the net profit attributable to shareholders of the parent company was -151.37 million yuan[5]. - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, was -166.75 million yuan last year[5]. - The company reported an operating revenue of 25.22 million yuan in the previous year[7]. Product Development - The rapid growth in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) which has been approved for sale[8]. - The production line for the related product is still in the capacity ramp-up phase, with capacity expected to be gradually released[8]. - The company continues to maintain high levels of investment in research and development[9].

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight increase in stock price and notable changes in financing activities on January 27, with a net financing outflow [1] - On January 27, He Yuan Bio's stock rose by 0.85%, with a trading volume of 217 million yuan, and a financing buy-in amount of 16.12 million yuan, while the financing repayment was 25.13 million yuan, resulting in a net financing outflow of 9.01 million yuan [1] - As of January 27, the total balance of margin trading for He Yuan Bio was 262 million yuan, which represents 7.72% of its circulating market value [1] Group 2 - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, marking an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.66 million yuan, reflecting a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also a decrease of 8.44% year-on-year [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has seen a continuous increase in stock price, with a 6.57% rise over three days, reaching a price of 83.00 yuan per share and a market capitalization of 29.673 billion yuan [1] - He Yuan Bio, established on November 16, 2006, specializes in the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with 75.44% of its revenue coming from recombinant human albumin [1] - The stock has a trading volume of 2.17 billion yuan and a turnover rate of 6.52% as of the report date [1] Group 2 - According to data, the Industrial Bank of China Credit Fund holds He Yuan Bio as its fifth-largest position, with 16,500 shares representing 0.02% of the fund's net value, yielding a floating profit of approximately 11,500 yuan today and 84,300 yuan over the three-day increase [2] - The fund, named Industrial Bank of China Science and Technology ETF Link A (011614), was established on March 5, 2021, with a current scale of 1.494 billion yuan and has achieved a year-to-date return of 13.15% [2] - The fund's one-year return is 54.14%, ranking 42 out of 209 in its category, while its total return since inception is 19.72% [2] Group 3 - The fund manager of Industrial Bank of China Science and Technology ETF Link A is Zhao Xu, who has a total tenure of 14 years and 106 days, managing assets totaling 68.885 billion yuan [3] - During Zhao Xu's tenure, the best fund return achieved was 233.59%, while the worst return was -84.87% [3]

Core Viewpoint - The company has exceeded 9,000 acres in medicinal rice cultivation and plans to gradually expand planting areas to match production capacity needs [1] Group 1: Company Operations - The company has completed the main structure of its 120-ton recombinant human albumin production line, with some equipment already in testing and others being gradually commissioned [1]

Group 1 - The company, Betta Pharmaceuticals, announced a commercial cooperation with Wuhan Heyuan Biotechnology Co., Ltd. for the regional commercialization of recombinant human albumin injection (rice-based) [1] - The recombinant human albumin product is considered groundbreaking, with clinical research showing efficacy comparable to human plasma albumin while overcoming safety risks associated with blood sources [1] - The company holds a 5.6% stake in Heyuan Biotechnology, which is currently under a lock-up period lasting one year post-IPO [1]